STXBP1 Encephalopathy Market Assessment 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. This comprehensive assessment of STXBP1 Encephalopathy provides an in-depth examination of the disease, including its pathophysiology, potential targets for treatment, and the prevalence of the condition both in the United States and across the EU5. This report grants a clearer understanding of the current status and implications of this rare neurodevelopmental condition. Current Treatments Reviewed and Unmet Needs Identified The report goes beyond mere statistics by dissecting the current treatment algorithms and the strengths and weaknesses of existing therapies. It also addresses the significant unmet needs within the area of STXBP1 Encephalopathy, identifying gaps in disease management and treatment that could represent opportunities for advancement in patient care. Pipeline Analysis: Emerging Therapies and Future Treatment Patterns A thorough analysis of the current pipeline for S
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis SuppurativaPR Newswire
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]Yahoo! Finance
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial SpondyloarthritisPR Newswire
- Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]Seeking Alpha